ProMIS Neurosciences Inc PMN

Acumen Pharmaceuticals Inc

[Speyeder999]

Thought some might be interested.....a few weeks back, I had posted something in regards with Acumen Pharma (a close competitor to Promis working on the same toxic oligomers targets) was going public in the near future .....well they did on July 1.

So the company market cap is sitting at 675M as of today with 37M shares outstanding. Not much information is disclosed on their site when compared to PROMIS, but they have initiated a Phase 1 clinical study of their lead drug (and only one from what I can see) .

So yeah, 10X more than PROMIS, but based on what? Who knows....but I hope that's where were heading in a years time!

Good luck (and patience) to all!

https://seekingalpha.com/article/4437332-acumen-pharmaceuticals-pursues-125-million-ipo

[M101]

Thanks for the reminder.    Their website is just a token but there is enough published on ACU-3B3 to identify where ACU-193 is headed.  https://www.nature.com/articles/s41598-018-22979-2  This single data point of IPO valuation is far more relevant to Promis than all the aducanumab spin. Competent management would be commenting to shareholders on this and the theory behind

[DavidKingCanada]

Great post!  M101 ???

[Gbathat]

That valuation certainly bodes well for PMN shareholders... we just need to get a partner with funding on board.  This should make it easier to attract major partnership/investment. For those that rip the Zack's $5.50 CAD estimate, take notes... we may be there by Phase I, especially if the COVID immunity test also gets traction. GLTA

[DavidKingCanada]

I would also agree with that assumption. Best of luck to all! 

[G1945V]

Does sounds very familiar! "Highly selective for oligomers, the toxic AO species, relative to other anti-amyloid mAbs that are less selective and/or target different amyloid species, such as monomers or plaques." Acumen Pharmaceutical Inc. PPS $18+. PMN $0.18+ Nasdaq is where we need to be. G1945V

[M101]

It's interesting that calcium screening identifies antibody candidates without otherwise characterizing the associated oligomer(s). So in theory PMN310 could be tested this way, or a model of ACU193 could be tested virtually against Promis' epitopes.    Assuming both companies believe they have the better antibody they could swap some info and both come out ahead. 

[G1945V]

https://www.evaluate.com/node/16950/pdf   Other oligomer-targeting projects are at the preclinical stage, and Acumen lists the likes of Alzinova, PromisNeurosciences, Kalgene Pharmaceuticals and Wren Therapeutics among its potential rivals. The last two groups are privately held – maybe a resurgence of interest in amyloid-beta could prompt them to follow Acumen onto the

[M101]

Re PMN competition, Wren is the only one starting from the same place with their "Third generation in silico antibody design platform generates antibodies against any epitope of an intrinsically disordered protein."  Everyone else starts from some theory where protein misfolding is not the  key step and opportunity.  And read their publication list for titles